SLV308 -: Antiparkinsonian -: Antidepressant -: Anxiolytic -: Dopamine D2 partial agonist -: 5-HT1A agonist

被引：9
|
作者：
Feenstra, R [1 ]
Ronken, E [1 ]
Koopman, T [1 ]
de Vries, M [1 ]
McCreary, A [1 ]
Stoker, M [1 ]
van Charldorp, K [1 ]
Long, S [1 ]
van Scharrenburg, G [1 ]
机构：
[1] Solvay Pharmaceut, NL-1380 DA Weesp, Netherlands
来源：
DRUGS OF THE FUTURE | 2001年 / 26卷 / 02期
关键词：
D O I：
10.1358/dof.2001.026.02.608830
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：128 / 132
页数：5
相关论文
共 50 条
  • [1] The in vitro characterization of SLV308:: A novel dopamine D2/D3 partial agonist and 5-HT1A full agonist for the treatment of Parkinson's disease
    McCreary, AC
    Glennon, JG
    Reindeers, JH
    Hesselink, M
    van Scharrenburg, G
    MOVEMENT DISORDERS, 2006, 21 : S79 - S80
  • [2] The in vivo characterization of SLV308:: A novel dopamine D2/D3 partial agonist and 5-HT1A full agonist for the treatment of Parkinson's disease
    McCreary, AC
    Johnston, L
    Glennon, J
    Rose, S
    Jackson, M
    Jenner, P
    MOVEMENT DISORDERS, 2006, 21 : S79 - S79
  • [3] A summary of the in vitro pharmacology of pardoprunox (SLV308): A novel dopamine D2/D3 partial agonist and 5-HT1A agonist for the treatment of Parkinson's disease
    McCreary, A.
    Glennon, J.
    Reinders, J. -H.
    Hesselink, M.
    van Scharrenburg, G.
    PARKINSONISM & RELATED DISORDERS, 2007, 13 : S139 - S140
  • [4] Effects of pardoprunox (SLV308), a partial D2/D3 receptor and 5-HT1A receptor agonist, on rat dopamine and serotonin neuronal activity
    Betry, C.
    Etievant, A.
    Lambas-Senas, L.
    McCreary, A.
    Haddjeri, N.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S117 - S117
  • [5] SLV308: A novel antiparkinsonian agent with antidepressant and anxiolytic properties
    McCreary, AC
    Ronken, E
    van der Heyden, J
    Herremans, A
    Tuinstra, T
    Long, S
    van Scharrenburg, G
    PARKINSON'S DISEASE, 2002, 1 : 51 - 58
  • [6] In Vivo Effects of Pardoprunox (SLV308), a Partial D2/D3 Receptor and 5-HT1A Receptor Agonist, on Rat Dopamine and Serotonin Neuronal Activity
    Betry, Cecile
    Etievant, Adeline
    Lambas-Senas, Laura
    Mccreary, Andrew C.
    Haddjeri, Nasser
    SYNAPSE, 2011, 65 (10) : 1042 - 1051
  • [7] An in vivo pharmacological evaluation of pardoprunox (SLV308) - A novel combined dopamine D2/D3 receptor partial agonist and 5-HT1A receptor agonist with efficacy in experimental models of Parkinson's disease
    Jones, C. A.
    Johnston, L. C.
    Jackson, M. J.
    Smith, L. A.
    van Scharrenburg, G.
    Rose, S.
    Jenner, P. G.
    McCreary, A. C.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 (08) : 582 - 593
  • [8] SLV308, a novel dopamine receptor stabilizer and 5-HT1A receptor agonist, has efficacy in animal models of anxiety and depression
    McCreary, A.
    Herremans, A.
    Glennon, J.
    van Scharrenburg, G.
    MOVEMENT DISORDERS, 2006, 21 : S642 - S642
  • [9] The partial dopamine agonist and full serotonin (5-HT)1A agonist pardoprunox (SLV308) has antidepressant and anxiolytie-like properties in rats, a detailed pharmacological evaluation
    Ashby, C. R., Jr.
    McCreary, A. C.
    MOVEMENT DISORDERS, 2009, 24 : S224 - S225
  • [10] In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride):: A novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist
    Glennon, Jeffrey C.
    Van Scharrenburg, Guus
    Ronken, Eric
    Hesselink, Mayke B.
    Reinders, Jan-Hendrik
    Van der Neut, Martina
    Long, Stephen K.
    Feenstra, Rolf W.
    McCreary, Andrew C.
    SYNAPSE, 2006, 60 (08) : 599 - 608
12345